Reuters' saying that Gazyva/Treanda vs Rituxan/Treanda raised 3-year survival from 92% to "only" 94% makes the benefit sound trifling, but it's actually a 25% reduction in the risk of death during the first three years.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.